| Leading the AI Applications Across the Drug Development Lifecycle session to discuss full-cycle clinical innovation strategies
| Unveiling core solutions including Maven Safety and presenting real-world data/AI use cases
| Strengthening global partnerships and industrial cooperation through booth operations and networking
JNPMEDI will showcase its vision for clinical trial innovation using artificial intelligence (AI) and digital technology, along with its core solutions, at the 2025 KoNECT-MOHW-MFDS International Conference (KIC 2025). The event will be held at the Lotte Hotel Seoul from September 22 to 24, featuring live demonstrations and interactive events.
Now in its 11th year, KIC is Asia's largest international clinical trial conference, co-hosted by the Ministry of Health and Welfare and the Ministry of Food and Drug Safety. Every year, over 1,500 participants gather to share the latest trends in global drug development and clinical trials.
Jung Kwon-ho, CEO of JNPMEDI, has served as a member of the Program Committee for three consecutive years, leading Korean companies to participate in major global clinical trial discussions. On September 24, the final day of the event, he will chair the session titled AI Applications Across the Drug Development Lifecycle: Practical Case Studies, discussing AI application cases and innovation strategies throughout the clinical lifecycle with global experts.
In the same session, Kim Se-eun, Senior Vice President of JNPMEDI, will present on Robotic Process Optimization in Clinical Trials, sharing specific ways AI-based automation technology enhances operational efficiency and data accuracy in clinical trials.
During the conference, JNPMEDI will participate in the exhibition booth and the Tech Fair. At the Tech Fair, the company will present and demonstrate the establishment of a Safety DB using Maven Safety. Maven Safety is a safety data management and adverse drug reaction reporting platform based on international standards, equipped to meet the latest FDA regulatory requirements. In addition, JNPMEDI will demonstrate major solutions covering the entire clinical trial process, allowing visitors to experience their use in actual clinical trial environments.
The company also plans to expand exchanges with global pharmaceutical, biotech, and medical device companies, research institutions, and CROs through networking programs and partnering meetings. Through these efforts, JNPMEDI aims to confirm domestic and international interest in the digital transformation of clinical trials and identify partnerships for joint research and global expansion strategies.
Jung Kwon-ho, CEO of JNPMEDI, stated that AI and data technology are now essential, not optional, in clinical trials. He added that through KIC 2025, JNPMEDI will share its solutions and experience while expanding cooperation to create new value in the global clinical trial environment.
| Leading the AI Applications Across the Drug Development Lifecycle session to discuss full-cycle clinical innovation strategies
| Unveiling core solutions including Maven Safety and presenting real-world data/AI use cases
| Strengthening global partnerships and industrial cooperation through booth operations and networking
JNPMEDI will showcase its vision for clinical trial innovation using artificial intelligence (AI) and digital technology, along with its core solutions, at the 2025 KoNECT-MOHW-MFDS International Conference (KIC 2025). The event will be held at the Lotte Hotel Seoul from September 22 to 24, featuring live demonstrations and interactive events.
Now in its 11th year, KIC is Asia's largest international clinical trial conference, co-hosted by the Ministry of Health and Welfare and the Ministry of Food and Drug Safety. Every year, over 1,500 participants gather to share the latest trends in global drug development and clinical trials.
Jung Kwon-ho, CEO of JNPMEDI, has served as a member of the Program Committee for three consecutive years, leading Korean companies to participate in major global clinical trial discussions. On September 24, the final day of the event, he will chair the session titled AI Applications Across the Drug Development Lifecycle: Practical Case Studies, discussing AI application cases and innovation strategies throughout the clinical lifecycle with global experts.
In the same session, Kim Se-eun, Senior Vice President of JNPMEDI, will present on Robotic Process Optimization in Clinical Trials, sharing specific ways AI-based automation technology enhances operational efficiency and data accuracy in clinical trials.
During the conference, JNPMEDI will participate in the exhibition booth and the Tech Fair. At the Tech Fair, the company will present and demonstrate the establishment of a Safety DB using Maven Safety. Maven Safety is a safety data management and adverse drug reaction reporting platform based on international standards, equipped to meet the latest FDA regulatory requirements. In addition, JNPMEDI will demonstrate major solutions covering the entire clinical trial process, allowing visitors to experience their use in actual clinical trial environments.
The company also plans to expand exchanges with global pharmaceutical, biotech, and medical device companies, research institutions, and CROs through networking programs and partnering meetings. Through these efforts, JNPMEDI aims to confirm domestic and international interest in the digital transformation of clinical trials and identify partnerships for joint research and global expansion strategies.
Jung Kwon-ho, CEO of JNPMEDI, stated that AI and data technology are now essential, not optional, in clinical trials. He added that through KIC 2025, JNPMEDI will share its solutions and experience while expanding cooperation to create new value in the global clinical trial environment.